Investigating a specific type of microglia involved in Alzheimer's disease
Official title: Contribution of a novel OPN-producing CD11c+ microglial subset to AD
Funded at Dana-Farber Cancer Inst · NIH-11011472 · Data updated 2026-11-12
This study is looking at special brain cells that might help cause Alzheimer's disease and is testing a new treatment that could reduce inflammation and improve thinking skills for people with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | February 1, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $455,377 |
| NIH project number | 5R01AG075837-02 |
| Project ID | NIH-11011472 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or those at risk of developing it.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
What this research studies
This research focuses on a unique subset of microglia that produce Osteopontin (OPN) and play a significant role in the progression of Alzheimer's disease (AD). By studying these cells in both a mouse model and human brain tissue, the research aims to understand how they contribute to inflammation and plaque formation in AD. The team will explore the potential of targeting OPN with therapeutic antibodies to reduce inflammation and improve cognitive function in affected individuals. This approach combines genetic analysis and therapeutic testing to identify new treatment strategies for Alzheimer's.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that reduce inflammation and improve cognitive function in Alzheimer's patients.
How similar studies have gone: Previous research has shown promising results in targeting microglial responses in Alzheimer's models, indicating potential for success in this novel approach.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Cantor, Harvey — Dana-Farber Cancer Inst
- Study coordinator: Cantor, Harvey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.